New data reveal that while most women with postpartum depression start antidepressant treatment, many discontinue treatment early—highlighting persistent gaps in postpartum care.
An open-label pilot study suggests that intravenous brexanolone may rapidly reduce psychotic, manic, and depressive symptoms in patients with postpartum psychosis, highlighting a potential new treatment option.
Developed for use in low-resource communities, interventions using non-specialist peers as providers can be used to deliver effective, evidence-based treatment for perinatal depression and anxiety.
Current guidelines list gabapentin as a recommended nonhormonal therapy for vasomotor symptoms in women who cannot or prefer not to use hormone therapy.
Lavender, used historically for anxiety, stress, depression, and sleep, may provide benefits through aromatherapy or oral forms. Evidence supports potential effects, though safety and efficacy in pregnancy and breastfeeding remain unclear.
Behavioral activation intervention, whether delivered by specialists or non-specialists, was effective for the treatment of perinatal depression and anxiety.
In a recent study from Mass General Hospital, researchers examined whether information included in the medical record at the time of discharge after delivery could help us to identify individuals at increased risk for postpartum depression.
Postpartum anxiety is a common and often under-recognized condition that affects a substantial proportion of new mothers.
Individuals with postpartum depression are being recruited for a clinical trial of a novel psychedelic compound, RE104.
Longer-term studies supporting the safety and efficacy of TMS during pregnancy are needed.
